Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

768
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

720
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

273
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
273
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

821
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
821
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

225
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mineralocorticoid Receptor Antagonist Use in Contemporary Heart Failure Care.

Cardiac failure review·2026
Same author

Role of systemic and epicardial adipose tissue in cardiometabolic disease.

Nature reviews. Cardiology·2026
Same author

Is Digitoxin the Fifth Pillar in Heart Failure With Reduced Ejection Fraction? A Response to the DIGIT-HF Trial.

Heart, lung & circulation·2026
Same author

iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025.

Heart views : the official journal of the Gulf Heart Association·2026
Same author

Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial.

European heart journal·2026
Same author

Sex differences in risk factor control and medication adherence post-ACS: insights from the TEXTMEDS randomised clinical trial.

Open heart·2026

Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

Hyponatraemia in heart failure.

Su Ling Tee1, Andrew Sindone2, Simon Roger3

  • 1Department of Cardiology, The Alfred, Melbourne, Victoria, Australia.

Internal Medicine Journal
|August 27, 2019
PubMed
Summary
This summary is machine-generated.

Hyponatraemia, or low sodium levels, is frequent in heart failure (HF) and indicates worse outcomes. This review explores its causes, consequences, and treatments in HF patients.

Keywords:
acute heart failurechronic heart failurehyponatraemia

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Related Experiment Videos

Last Updated: Jan 20, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Hyponatraemia (low sodium) is prevalent in heart failure (HF), affecting over 20% of hospitalized patients.
  • Low sodium levels in HF serve as a significant marker for increased patient morbidity and mortality.
  • The neurohormonal dysregulation in HF contributes to the development of hyponatraemia.

Purpose of the Study:

  • To review the pathophysiology of hyponatraemia in HF, focusing on neurohormonal activation.
  • To discuss the clinical implications of persistent hyponatraemia in heart failure patients.
  • To outline current and potential treatment strategies for hyponatraemia in the context of HF management.

Main Methods:

  • Literature review of studies on hyponatraemia in heart failure.
  • Analysis of pathophysiological mechanisms involving neurohormonal cascades.
  • Synthesis of clinical data on morbidity, mortality, and treatment outcomes.

Main Results:

  • Hyponatraemia arises from activated neurohormonal systems (e.g., renin-angiotensin-aldosterone, sympathetic nervous system, arginine vasopressin) in HF.
  • Sustained low sodium levels are linked to prolonged hospital stays, increased readmissions, and higher mortality rates.
  • Management strategies are evolving, with a focus on addressing underlying HF and specific hyponatraemia treatments.

Conclusions:

  • Hyponatraemia is a critical complication of heart failure with significant prognostic implications.
  • Understanding the neurohormonal basis of hyponatraemia is key to effective management.
  • Further research and tailored therapeutic approaches are needed for optimal patient outcomes.